| scholarly article | Q13442814 |
| P50 | author | Tullia Todros | Q41277675 |
| P2093 | author name string | Francesco Bennardello | |
| Stefania Villa | |||
| Giuseppe Curciarello | |||
| Serelina Coluzzi | |||
| Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) and Italian Society of Gynaecology and Obstetrics (SIGO) working group | |||
| P2860 | cites work | An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations | Q80165120 |
| Determinants of the middle cerebral artery peak systolic velocity in the human fetus | Q81546562 | ||
| The kinetics of routine antenatal prophylactic intramuscular injections of polyclonal anti-D immunoglobulin | Q82201432 | ||
| Severe hemolytic disease of the newborn in a group B African-American infant delivered by a group O mother | Q83304810 | ||
| Single versus multiple dose intravenous immunoglobulin in combination with LED phototherapy in the treatment of ABO hemolytic disease in neonates | Q84206635 | ||
| Hemolytic disease of the fetus/newborn: reflections on articles from TRANSFUSION Volume 1 | Q84815056 | ||
| BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn | Q87571581 | ||
| Management of Rhesus Alloimmunization in Pregnancy | Q22242754 | ||
| Anti-D administration after spontaneous miscarriage for preventing Rhesus alloimmunisation | Q24198904 | ||
| Anti-D administration in pregnancy for preventing Rhesus alloimmunisation | Q24200690 | ||
| Intramuscular versus intravenous anti-D for preventing Rhesus alloimmunization during pregnancy | Q24201509 | ||
| Grading quality of evidence and strength of recommendations | Q24562409 | ||
| Prenatal Diagnosis of Fetal RhD Status by Molecular Analysis of Maternal Plasma | Q28314918 | ||
| Noninvasive techniques to detect fetal anemia due to red blood cell alloimmunization: a systematic review | Q31005852 | ||
| Immunoglobulin infusion for isoimmune haemolytic jaundice in neonates | Q32166039 | ||
| Prevention of Rh alloimmunization. | Q33188512 | ||
| Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology | Q33336231 | ||
| Guidelines for the use of platelet transfusions | Q33348675 | ||
| The role of antenatal immunoprophylaxis in the prevention of maternal-foetal anti-Rh(D) alloimmunisation. | Q33603109 | ||
| Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses | Q33885603 | ||
| Anti-D administration after childbirth for preventing Rhesus alloimmunisation | Q33906600 | ||
| Non-anti-D antibodies in red-cell alloimmunization | Q34032308 | ||
| Molecular determination of RHD zygosity:predicting risk of hemolytic disease of the fetus and newborn related to anti‐D | Q34149450 | ||
| Hemolytic disease of the fetus and newborn: Current trends and perspectives | Q34185118 | ||
| Etiology and outcome of hydrops fetalis | Q34303534 | ||
| Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia | Q34460658 | ||
| Recommendations for the transfusion management of patients in the peri-operative period. I. The pre-operative period | Q34492729 | ||
| Fetal genotyping for the K (Kell) and Rh C, c, and E blood groups on cell-free fetal DNA in maternal plasma | Q34706395 | ||
| Management of rhesus alloimmunization in pregnancy | Q34831214 | ||
| Recommendations for the transfusion management of patients in the peri-operative period. II. The intra-operative period | Q34988663 | ||
| A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative. | Q35084194 | ||
| Recommendations for the transfusion management of patients in the peri-operative period. III. The post-operative period | Q35106170 | ||
| Maternal anti-D prophylaxis during pregnancy does not cause neonatal haemolysis | Q35290338 | ||
| Thirty-five years of Rh prophylaxis | Q35594663 | ||
| Management of pregnancies complicated by anti-E alloimmunization | Q35996356 | ||
| Red blood cell alloimmunization in pregnancy | Q36205961 | ||
| Rate of RhD sensitisation before and after implementation of a community based antenatal prophylaxis programme | Q36247576 | ||
| The Lui elution technique. A simple and efficient method for eluting ABO antibodies. | Q54030290 | ||
| Prenatal Determination of Fetal RhD Type by DNA Amplification | Q57208591 | ||
| RhD Hemolytic Disease of the Newborn | Q59406030 | ||
| Prenatal and perinatal immunohematology: recommendations for serologic management of the fetus, newborn infant, and obstetric patient | Q68449623 | ||
| Clinical high-risk designation does not predict excess fetal-maternal hemorrhage | Q70159864 | ||
| Fetomaternal transplacental hemorrhage during pregnancy and after delivery | Q70310771 | ||
| Erythropoietic suppression in fetal anemia because of Kell alloimmunization | Q72059544 | ||
| Prenatal determination of fetal RhD status by analysis of peripheral blood of rhesus negative mothers | Q72217432 | ||
| Causes and clinical consequences of Rhesus (D) haemolytic disease of the newborn: a study of a Scottish population, 1985-1990 | Q72490803 | ||
| Detection of fetal hemorrhage in Rh immune globulin candidates. A rosetting technique using enzyme-treated Rh2Rh2 indicator erythrocytes | Q72682855 | ||
| Is a third-trimester antibody screen in Rh+ women necessary? | Q73324449 | ||
| How concerned should we be about missing antibodies to low incidence antigens? | Q73567604 | ||
| Ultrasonographic surveillance in red blood cell alloimmunization | Q73873416 | ||
| Antenatal antibody screening | Q74075958 | ||
| Use of the gel agglutination technique for determination of fetomaternal hemorrhage | Q74413918 | ||
| Detection of antibodies in acid eluates with the gel microcolumn assay | Q74534392 | ||
| [Demonstration of fetal hemoglobin in erythrocytes of a blood smear] | Q74570391 | ||
| A simple method to estimate volume for fetal intravascular transfusions | Q74743981 | ||
| Use of Rh immune globulin: ASCP practice parameter. American Society of Clinical Pathologists | Q77204575 | ||
| Practice guidelines for prenatal and perinatal immunohematology, revisited | Q77296713 | ||
| Recommendations for the use of anti-D immunoglobulin for Rh prophylaxis. British Blood Transfusion Society and the Royal College of Obstetricians and Gynaecologists | Q77365518 | ||
| The prevention of Rh haemolytic disease of the fetus and newborn--general background | Q77720009 | ||
| Addendum for guidelines for blood grouping and red cell antibody testing during pregnancy. BCSH Transfusion Task Force | Q78068648 | ||
| ACOG practice bulletin. Prevention of Rh D alloimmunization. Number 4, May 1999 (replaces educational bulletin Number 147, October 1990). Clinical management guidelines for obstetrician-gynecologists. American College of Obstetrics and Gynecology | Q78161956 | ||
| Diagnosing hemolytic disease of the fetus--time to put the needles away? | Q79893345 | ||
| Rh-immunoglobulin: Rh prophylaxis | Q36353416 | ||
| Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force | Q36372988 | ||
| Comparative genomic hybridization and prenatal diagnosis | Q36443234 | ||
| Do Rh-negative women with first trimester spontaneous abortions need Rh immune globulin? | Q36513535 | ||
| How I manage donors and patients with a weak D phenotype | Q36629406 | ||
| Flow cytometry in diagnosis and management of large fetomaternal haemorrhage | Q36789102 | ||
| A simple approach to confirm the presence of anti-D in sera with presumed anti-D+C specificity | Q37059259 | ||
| Recommendations for the transfusion of red blood cells | Q37119693 | ||
| Fetal anemia due to non-Rhesus-D red-cell alloimmunization | Q37132178 | ||
| Recommendations for the transfusion of plasma and platelets | Q37209117 | ||
| Survey on the prevention and incidence of haemolytic disease of the newborn in Italy | Q37306744 | ||
| Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation | Q37390911 | ||
| Anti-Kell in pregnancy | Q37664267 | ||
| Prevention of RhD alloimmunization in RhD negative women | Q37743188 | ||
| Fetomaternal hemorrhage: incidence, risk factors, time of occurrence, and clinical effects | Q37929442 | ||
| The direct antiglobulin test: a critical step in the evaluation of hemolysis | Q38008281 | ||
| Management and prevention of red cell alloimmunization in pregnancy: a systematic review | Q38054551 | ||
| Therapeutic management of fetal anemia: review of standard practice and alternative treatment options | Q38055055 | ||
| Variants of RhD--current testing and clinical consequences | Q38083742 | ||
| The prevention of Rh immunization | Q39341842 | ||
| Identification and quantification of anti-D, -C and -G in alloimmunized pregnant women | Q40659267 | ||
| Haemolytic disease of the fetus and newborn due to anti-Fy(a) and the potential clinical value of Duffy genotyping in pregnancies at risk | Q40866115 | ||
| A retrospective study to determine the risk of red cell alloimmunization and transfusion during pregnancy | Q40878868 | ||
| Rh hemolytic disease of the newborn--the disease eradicated by immunology | Q41292407 | ||
| Recommendations for the use of albumin and immunoglobulins | Q42671923 | ||
| Effect on primary Rh immunization of delayed administration of anti-Rh | Q43433658 | ||
| Controversies in Rh prophylaxis. Who needs Rh immune globulin and when should it be given? | Q43618356 | ||
| Transplacental haemorrhage in spontaneous and induced abortion | Q43863111 | ||
| Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial | Q44532600 | ||
| Quantitation of fetal-maternal hemorrhage by flow cytometry. A simple and accurate method | Q44660512 | ||
| Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories. British Committee for Standards in Haematology | Q45141633 | ||
| Severe hemolytic disease of fetus and newborn caused by red blood cell antibodies undetected at first-trimester screening (CME). | Q45871905 | ||
| Failures of intravenous Rh immune globulin prophylaxis: an analysis of the reasons for such failures | Q46376527 | ||
| Studies on Rh prophylaxis. 1. Relationship between doses of anti-Rh and size of antigenic stimulus | Q47379571 | ||
| Prediction of fetal anemia in rhesus disease by measurement of fetal middle cerebral artery peak systolic velocity | Q47631140 | ||
| Maternal Kell blood group alloimmunization | Q47874507 | ||
| Consequences of being Rhesus D immunized during pregnancy and how to optimize new prevention strategies. | Q50489938 | ||
| [High-dose intravenous immunoglobulin therapy and neonatal jaundice due to red blood cell alloimmunization]. | Q50603672 | ||
| Routine antenatal Rhesus D immunoglobulin prophylaxis: the results of a prospective 10 year study. | Q50650252 | ||
| [Prevention of fetomaternal rhesus-D allo-immunization. Practical aspects] | Q50741629 | ||
| Doppler ultrasonography versus amniocentesis to predict fetal anemia. | Q53252870 | ||
| Diagnostic accuracy of noninvasive fetal Rh genotyping from maternal blood--a meta-analysis. | Q53597278 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 109-134 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Blood transfusion = Trasfusione del sangue | Q26842792 |
| P1476 | title | Recommendations for the prevention and treatment of haemolytic disease of the foetus and newborn | |
| P478 | volume | 13 |
| Q37508079 | Anti-D Antibodies in Pregnant D Variant Antigen Carriers Initially Typed as RhD. |
| Q56524754 | Frequency of Red Cell Alloantibodies in Pregnant Females of Navsari District: An Experience that Favours Inclusion of Screening for Irregular Erythrocyte Antibody in Routine Antenatal Testing Profile |
| Q64951331 | Hyporegenerative anemia and other complications of rhesus hemolytic disease: to treat or not to treat is the question. |
| Q96138426 | Recombinant anti-D for prevention of maternal-foetal Rh(D) alloimmunization: a randomized multi-centre clinical trial |
| Q91606054 | The contribution of iron deficiency to the risk of peripartum transfusion: a retrospective case control study |
Search more.